This initial safety study involves single injections of Protectan CBLB502 in ascending dose groups of six healthy volunteers each. Participants in the study are assessed for adverse side
This appointment, which represents a new position on the board, brings the total number of company directors to nine, with six serving independently. Current chairman Gregory Pusey is
Following an oral hearing, the opposition division of the European patent Office has announced its decision to revoke a European patent in its entirety. This patent, which is
Michael Lutz, global manager of Cogenics, said: “Our partnership with SinoGenoMax provides us with an established presence in China and an experienced international service partner who operates with
Mr Altig is the CFO at Pelican Life Sciences, a manufacturer of microbiological and molecularbiological consumables. Mr Altig has also served as a director of Optimer Pharmaceuticals since
Through the agreement, Hitachi Medical will market, sell and service the Hi Art system, which facilitates highly precise, computed tomography-guided radiation therapy for a wide range of clinical
Under the umbrella of Alliance HealthCare Services, the company’s imaging and oncology divisions will continue to operate under the names of Alliance Imaging and Alliance Oncology. The company
APP’s rocuronium is AP-rated and preservative-free, and is marketed in two dosage forms, 50mg/5ml and 100mg/10ml. It is a nondepolarizing neuromuscular blocking agent that unlike other NMBA’s provides
The agreement grants Hamilton Thorne (HT) the exclusive rights to sell the confocal product to the regenerative medical research market that Hamilton Thorne serves worldwide. Current methods of
According to a new development and licensing agreement, RaySearch will develop software modules for Model-Based Segmentation (MBS) and treatment planning of Volumetric Modulated Arc Therapy (VMAT) for Oncentra
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.